Patent application number | Description | Published |
20080220433 | DETECTING METHYLATED MAMMALIAN NUCLEIC ACID IN STOOL - This document includes methods and materials for enriching and detecting cancer markers. For example, this document includes methods and materials for enriching methylated mammalian nucleic acid from stool samples. | 09-11-2008 |
20080254547 | SUPRACOLONIC AERODIGESTIVE NEOPLASM DETECTION - The invention provides methods and materials for detecting supracolonic aerodigestive premalignant and malignant neoplasms. Specifically, the invention provides methods and materials for determining whether a stool sample from a mammal contains a neoplasm-specific marker from a neoplasm located in the supracolonic aerodigestive tissue of a mammal. | 10-16-2008 |
20100121046 | COLLECTING AND PROCESSING COMPLEX MACROMOLECULAR MIXTURES - This document provides methods and materials involved in collecting and processing complex macromolecular mixtures (e.g., stool samples). For example, stool collection devices, buffers for stabilizing nucleic acid and polypeptides present in stool, and kits for using sequence-specific capture probes (e.g., nucleic acid sequences designed to hybridize with particular target nucleic acids) to capture target nucleic acids directly from complex macromolecular mixtures (e.g., stool samples) without the need to perform prior steps to enrich, isolate, or purify the nucleic acid component are provided. | 05-13-2010 |
20100297658 | DETECTING METHYLATED MAMMALIAN NUCLEIC ACID IN STOOL - This document includes methods and materials for enriching and detecting cancer markers. For example, this document includes methods and materials for enriching methylated mammalian nucleic acid from stool samples. | 11-25-2010 |
20110183328 | DETECTING NEOPLASM - This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided. | 07-28-2011 |
20120028367 | REMOVING POLYPEPTIDES FROM STOOL - This document provides methods and materials involved in removing polypeptides (e.g., high abundance polypeptides) from stool samples. For example, methods and materials for preparing a stool sample for detecting polypeptides of low abundance are provided. | 02-02-2012 |
20120196756 | DIGITAL SEQUENCE ANALYSIS OF DNA METHYLATION - The present invention relates to methods and compositions for determination of and uses of specific methylation patterns indicative of adenoma and carcinoma. In particular, the invention relates to analysis of defined CpG loci that are coordinately methylated in DNAs from cancer and adenoma samples, methods for identifying coordinately methylated loci, and methods of using analysis of coordinately methylated loci in one or more marker regions in the design of assays for adenoma and cancer. | 08-02-2012 |
20120288956 | COLLECTING AND PROCESSING COMPLEX MACROMOLECULAR MIXTURES - This document provides methods and materials involved in collecting and processing complex macromolecular mixtures (e.g., stool samples). For example, stool collection devices, buffers for stabilizing nucleic acid and polypeptides present in stool, and kits for using sequence-specific capture probes (e.g., nucleic acid sequences designed to hybridize with particular target nucleic acids) to capture target nucleic acids directly from complex macromolecular mixtures (e.g., stool samples) without the need to perform prior steps to enrich, isolate, or purify the nucleic acid component are provided. | 11-15-2012 |
20130012410 | METHODS AND MATERIALS FOR DETECTING COLORECTAL CANCER AND ADENOMA - The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers (e.g., markers associated with colorectal cancer, markers associated with adenoma) in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals (e.g., humans) having a colorectal neoplasm by detecting the presence and level of indicators of colorectal neoplasia such as, for example, long DNA (e.g., quantified by Alu PCR) and the presence and level of tumor-associated gene alterations (e.g., mutations in KRAS, APC, melanoma antigen gene, p53, BRAF, BAT26, PIK3CA) or epigenetic alterations (e.g., DNA methylation) (e.g., CpG methylation) (e.g., CpG methylation in coding or regulatory regions of bmp-3, bmp-4, SFRP2, vimentin, septin9, ALX4, EYA4, TFPI2, NDRG4, FOXE1) in DNA from a stool sample obtained from the mammal. | 01-10-2013 |
20130244235 | METHODS AND MATERIALS FOR NONINVASIVE DETECTION OF COLORECTAL NEOPLASIA ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE - The present invention provides methods and materials related to the detection of colorectal neoplasia (CRN) associated with inflammatory bowel disease (IBD). The present invention provides markers specific for colorectal neoplasia associated with inflammatory bowel disease in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals (e.g., humans) having colorectal neoplasia associated with inflammatory bowel disease by detecting the presence and level of indicators of colorectal neoplasia such as, for example, epigenetic alterations (e.g., DNA methylation) (e.g., CpG methylation) (e.g., CpG methylation in coding or regulatory regions of BMP3, NDRG4, vimentin, EYA4) in DNA from a stool sample obtained from the mammal. | 09-19-2013 |
20140057262 | METHODS AND MATERIALS FOR USING THE CONTENTS OF PHAGOCYTES TO DETECT NEOPLASMS - This document provides methods and materials related to detecting premalignant or malignant neoplasms (e.g., colorectal and pancreatic cancer). For example, methods and materials for assessing the contents of phagocytes for the presence of one or more biological markers (e.g., Alu repeats or methylated nucleic acid) of premalignant or malignant neoplasms are provided. | 02-27-2014 |
20140205517 | COLLECTING AND PROCESSING COMPLEX MACROMOLECULAR MIXTURES - This document provides methods and materials involved in collecting and processing complex macromolecular mixtures (e.g., stool samples). For example, stool collection devices, buffers for stabilizing nucleic acid and polypeptides present in stool, and kits for using sequence-specific capture probes (e.g., nucleic acid sequences designed to hybridize with particular target nucleic acids) to capture target nucleic acids directly from complex macromolecular mixtures (e.g., stool samples) without the need to perform prior steps to enrich, isolate, or purify the nucleic acid component are provided. | 07-24-2014 |
20140221252 | DETECTING NEOPLASM - This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided. | 08-07-2014 |
20140274748 | DETECTING NEOPLASM - Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as pancreatic and colorectal cancer. | 09-18-2014 |
20150072866 | MARKER PANEL FOR DETECTING CANCER - Provided herein is technology relating to detecting cancer and particularly, but not exclusively, to methods for detecting colorectal cancer by evaluating multiple markers in paired plasma and stool samples. In particular, the technology relates to CRC screening by assaying plasma for methylated Septin 9 and assaying stool DNA for methylated vimentin, NDRG4, BMP3, and/or TFPI2. | 03-12-2015 |
20150354013 | DETECTING NEOPLASM - This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided. | 12-10-2015 |
20160040246 | DETECTING NEOPLASM - Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as pancreatic and colorectal cancer. Accordingly, provided herein is technology for pancreatic cancer screening markers and other gastrointestinal cancer screening markers that provide a high signalto-noise ratio and a low background level when detected from samples taken from a subject (e.g., stool sample). As described herein, the technology provides a number of methylated DNA markers and subsets thereof (e.g., sets of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more markers) with high discrimination for G1 neoplasms overall and/or at individual tumor sites. | 02-11-2016 |
20160090634 | DETECTING CHOLANGIOCARCINOMA - Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting neoplasms such as cholangiocarinoma. | 03-31-2016 |
Patent application number | Description | Published |
20090136486 | Biomarkers for human papilloma virus-associated cancer - Cervical cancer cells and HPV | 05-28-2009 |
20090148950 | PRODUCTION OF PACKAGED DNA SEQUENCES - A method of producing a packaged DNA sequence is disclosed. In one embodiment, the method comprises the steps of: (a) selecting a DNA sequence to be packaged and a papillomaviral capsid sequence, wherein the DNA sequence to be packaged is between 7 Kb-8.5 Kb, (b) co-transfecting the products of step (a) into transfectable cells, wherein the DNA sequence is packaged, and (c) purifying packaged particles. | 06-11-2009 |
20100047838 | YEAST GENES THAT AFFECT VIRAL REPLICATION - An antiviral agent comprising an altered MAB1, MAB2, MAB3, or OLE1 gene, gene homologs or related genes is disclosed. In another embodiment, the present invention is a method of creating a virus resistant organism comprising creating a transgenic organism comprising an antiviral agent selected from the group of altered MAB1 genes, MAB2 genes, MAB3 genes or OLE1 genes, homologs of these genes, related genes and combinations of these genes and homologs. | 02-25-2010 |
20110165220 | DRUGS TO PREVENT HPV INFECTION - A method of inhibiting HPV virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of a compound selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14. In another embodiment, the method involves administering an inhibitor selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14 to a susceptible tissue or cell. | 07-07-2011 |
20110165266 | SCREEN FOR INHIBITORS OF HIV REPLICATION - A method of screening test chemicals or compounds as inhibitors of HIV replication is disclosed. In one embodiment, the method comprises the step of determining whether the test chemical or compound is a sulfonation inhibitor. In another embodiment, the invention is a method of treating an HIV infected individual to reduce HIV replication comprising the step of treating the individual with an effective amount of sulfonation inhibitor. | 07-07-2011 |
20110189258 | METHOD AND COMPOSITIONS FOR INHIBITION OF DOUBLE STRANDED DNA VIRUSES - A method of inhibiting double-stranded DNA virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of an inhibitor selected from the group of G1, S, G2, and M cell cycle inhibitors. In another embodiment, the method involves administering an inhibitor selected from the group of G1, S, G2, and M cell cycle inhibitors to a susceptible tissue or cell. | 08-04-2011 |
20110301059 | Biomarkers For Human Papilloma Virus-Associated Cancers - Cervical cancer cells and HPV | 12-08-2011 |
20150297602 | DRUGS TO PREVENT HPV INFECTION - A method of inhibiting HPV virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of a compound selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14. In another embodiment, the method involves administering an inhibitor selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14 to a susceptible tissue or cell. | 10-22-2015 |